Skip to content
Screener

BioLife Solutions BLFS Amortized cost of available-for-sale debt securities, current

Amortized cost of available-for-sale debt securities, current at other companies

Microvision logo
MicrovisionMVIS
$42.45M+110%
BioLife Solutions logo
BioLife SolutionsBLFS
$58.49M+17.4%
PubMatic logo
PubMaticPUBM
$17.54M-35.3%
Chime Financial, Inc. logo
Chime Financial, Inc.CHYM
$527.78M+135%
Globus Medical logo
Globus MedicalGMED
$87.46M
Marcus & Millichap logo
Marcus & MillichapMMI
$57.29M-58.0%

Other financials

Income statement

See full
Revenue$28.5M+21.5%
Gross profit$18.3M+20.0%
Operating income$1.7M+111%
Net income$45.1M+385%
EPS (diluted)$0.91+376%

Balance sheet

See full
Cash & equivalents$24.0M-24.8%
Total debt$15.7M-33.9%
Total equity$420.0M+21.0%
Total assets$447.5M+15.6%

Cash flow

See full
Operating cash flow$6.3M-13.8%
CapEx$1.0M-40.2%
Free cash flow$5.3M-5.7%

Valuation

See full
Market cap$1.7B+56.2%
Enterprise value$1.69B+56.6%
P/E54.6×
P/S16.5×+3.2×

Profitability

See full
Gross margin67.2%
Operating margin1.6%
Net margin-68.7%
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0.0×
Current ratio9.7×+5.3×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent.

The source filing: BioLife Solutions’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:22 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054355
(In thousands)Amortized CostGross unrealized / GainsGross unrealized / LossesEstimated Fair Value
U.S. government securities$11,781$4$(28)$11,757
Corporate debt securities37,2014(47)37,158
Other debt securities9,5082(6)9,504
Total short-term58,49010(81)58,419
Available-for-sale securities, long-term
U.S. government securities9,679(46)9,633
Corporate debt securities19,578(87)19,491
Other debt securities1,536(6)1,530

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is BioLife Solutions's amortized cost of available-for-sale debt securities, current?
BioLife Solutions (BLFS) reported amortized cost of available-for-sale debt securities, current of $58.49M in Q2 2026.
How has BioLife Solutions's amortized cost of available-for-sale debt securities, current changed year-over-year?
BioLife Solutions's amortized cost of available-for-sale debt securities, current increased by 17.4% year-over-year, from $49.83M to $58.49M.
What is the long-term trend for BioLife Solutions's amortized cost of available-for-sale debt securities, current?
Over 3 years (2022 to 2025), BioLife Solutions's amortized cost of available-for-sale debt securities, current has grown at a 8.8% compound annual growth rate (CAGR), from $43.31M to $55.8M.
What does amortized cost of available-for-sale debt securities, current mean?
Amortized cost of available-for-sale debt securities, current

Ask your AI about BioLife Solutions's amortized cost of available-for-sale debt securities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude